A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
MEK抑制剂selumetinib联合pembrolizumab治疗晚期或转移性实体瘤的1期临床试验
期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-024-01428-0
Chénard-Poirier, Maxime; Hansen, Aaron R; Gutierrez, Martin E; Rasco, Drew; Xing, Yan; Chen, Lin-Chi; Zhou, Heng; Webber, Andrea L; Freshwater, Tomoko; Sharma, Manish R